US EditionAP Biosciences charts course for safer CD137 bispecifics with T-cube
Summary by Drug Discovery and Development
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
AP Biosciences charts course for safer CD137 bispecifics with T-cube
AP Biosciences is building the protocol around one key objective: confirm that conditional CD137 agonism, a tumor-restricted T-cell costimulation, can be delivered safely in patients whose HER2-positive solid tumors express the p95HER2 variant, a truncated, drug-resistant form of HER2. To that end, it recently dosed the first patient in the Phase 1/2 trial of its… The post AP Biosciences charts course for safer CD137 bispecifics with its T-cube …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage